SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2018. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Nov’ 2018 at Hyderabad.
HYDERABAD, INDIA (14 Nov’ 2018) – Suven Life Sciences Ltd, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2018. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Nov’ 2018 at Hyderabad.
Financial Highlights for the Half year ended September’ 2018:
Growth in revenue INR 2959 Mn vs INR 2586 Mn - up by 14.41% Growth in PAT INR 567 Mn vs INR 613 Mn - down by 7.44% Growth in EBIDTA INR 974 Mn vs INR 1010 Mn - down by 3.64%
Financial Highlights for the 2nd Quarter ended September’ 2018 (QoQ):
Growth in revenue INR 961 Mn vs INR 1120 Mn - down by 14.18% Growth in PAT INR 179 Mn vs INR 317 Mn - down by 43.45% Growth in EBIDTA INR 310 Mn vs INR 501 Mn - down by 38.16%
Suven’s major thrust on innovative R&D in Drug Discovery continues with a spending of INR 284 Mn (9.59% on income) for the half year ended September 2018.
For more information on Suven please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive
CIN: L24110TG1989PLC009713
6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com
